NCT02703272 2022-12-02
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 3 Terminated
Janssen Research & Development, LLC
University of Florida
French Innovative Leukemia Organisation
Alliance for Clinical Trials in Oncology
SWOG Cancer Research Network
Gustave Roussy, Cancer Campus, Grand Paris